Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

Gaucher Disease Clinical Trial

Official title:

A Multicenter Open-Label Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00478647
• Other study ID #: TKT034
• Secondary ID: 2006-006304-11
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: July 25, 2007
• Est. completion date: June 26, 2009

Study information

• Verified date: May 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the safety and efficacy of every other week dosing of GA-GCB (velaglucerase alfa) in participants with type 1 Gaucher disease who were previously treated with imiglucerase.

Description:

Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and does not involve the CNS. Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. GA-GCB contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This study was designed to determine the safety of GA-GCB in men, women, and children with Type 1 Gaucher disease who were previously treated with imiglucerase. Each participant's duration of treatment will be 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 26, 2009
• Est. primary completion date: June 26, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

Includes:

• The participant has a documented diagnosis of type 1 Gaucher disease, as determined by deficient glucocerebrosidase (GCB) activity relative to normal as measured in leukocytes or by genotype analysis and the participant/legal guardian is willing and able to provide written informed consent prior to initiating any study-related procedures

• The participant has received consistent treatment with imiglucerase at a dose = 60 U/kg and = 15 U/kg every other week for a minimum of 30 consecutive months. Participants who are anti-imiglucerase antibody positive will be allowed to enter this study

• The participant is at least 2 years of age

• Female participants of child-bearing potential agree to use a medically acceptable method of contraception. Male participants must agree to use a medically acceptable method of birth control

• Participant must be sufficiently co-operative to participate in the study as judged by the Investigator.

Exclusion Criteria:

Includes:

• The participant has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease

• The participant has received treatment with any investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted

• Participant is HIV positive

• Participant is hepatitis B/C positive

• The participant presents with sustained iron, folic acid and/or vitamin B12 deficiency-related anemia during Screening

• The participant, participant's parent(s), or participant's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study

• The participant has a significant comorbidity that might affect study data or confound the study results

• The participant is unable to comply with the protocol or is otherwise unlikely to complete the study, as determined by the Investigator

• The participant has experienced an anaphylactic/anaphylactoid reaction during treatment with imiglucerase

• The participant has received miglustat during the 6 months prior to study enrollment

• The participant has an active, clinically significant spleen infarction

• The participant has active, progressive bone necrosis

• The participant is a pregnant and/or lactating female

Related Conditions & MeSH terms

• Gaucher Disease

Intervention

Biological:
• GA-GCB (velaglucerase alfa)
15-60 U/kg, every other week via intravenous infusion

Locations

Country	Name	City	State
Israel	Shaare Zedek Medical Center	Jerusalem
Poland	Children's Memorial Health Institute	Warszawa
Spain	Hospital Universitario Miguel Servet	Zaragoza
United Kingdom	The Royal Free Hospital	London
United States	Feinberg School of Medicine	Chicago	Illinois
United States	Cincinatti Children's Hospital	Cincinnati	Ohio
United States	Emory University	Decatur	Georgia
United States	Texas Children's Hospital	Houston	Texas
United States	Children's Mercy Hospital and Clinic	Kansas City	Missouri
United States	Regional Metabolic Center	Los Angeles	California
United States	Children's Hospital of Wisconsin	Milwaukee	Wisconsin
United States	Children's of Minnesota	Minneapolis	Minnesota
United States	NYU School of Medicine	New York	New York
United States	Children's Hospital Oakland	Oakland	California
United States	Medical Genetics/Pediatrics	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Countries where clinical trial is conducted

United States,  Israel,  Poland,  Spain,  United Kingdom, 

References & Publications (1)

Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA. Safety and efficacy of velaglucerase alf — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Participants Who Experienced at Least One Adverse Event	Safety was assessed throughout the study by assessments including adverse events, concomitant medication use, and vital signs. Additional safety assessments, including 12-lead ECGs, physical examinations, clinical laboratory tests and determination of the presence of anti-velaglucerase alfa antibodies. Refer to Adverse event section for further details.	Week 53
Secondary	Change From Baseline to Week 53 in Hemoglobin Concentration		Week 53
Secondary	Percent Change From Baseline to Week 53 in Platelet Count		Week 53
Secondary	Percent Change From Baseline to Week 51 in Normalized Liver Volume	Liver volume has been normalized for percentage (%) of body weight. Liver size relative to body weight= (Liver volume [cc]/Body weight [kg])*100	Week 51
Secondary	Percent Change From Baseline to Week 51 in Normalized Spleen Volume	Spleen volume has been normalized for percentage (%) of body weight. Spleen size relative to body weight= (Spleen volume [cc]/Body weight [kg])*100	Week 51